iCare ILLUME screening solution instantly detects early signs of DR, AMD, and Glaucoma

How does iCare ILLUME work?

The AI detects early signs of diabetic retinopathy, AMD and glaucoma instantly and classifies the results according to severity based on international classifications. This allows healthcare professionals to focus on patients who are most in need of specialized care.

With iCare ILLUME, you benefit from efficient processing for higher throughput and reliable results that match the level of a professional human grader.


Get a report with severity scoring

The iCare ILLUME solution uses partner’s AI deep learning technology to analyze the fundus images captured by iCare DRSplus and generates a patient report with severity scoring for AMD and DR based on international standards (ICDR, AREDS). For glaucoma (GLC), the AI will indicate whether there is a glaucoma suspicion.

Diabetic retinopathy

DR is the leading cause of vision loss in adults aged 20–74 years. Over one-third of an estimated 285 million people worldwide with diabetes show signs of DR. DR is on the rise due to the increasing prevalence of diabetes, the aging population, and the increasing life expectancy of those with diabetes.

Age-related macular degeneration

AMD is a progressive, incurable disease, leading to severe visual impairment. It affects an estimated 170 million individuals worldwide and is one of the leading causes of visual disability. High prevalence makes periodic screening crucial to prevent the growing healthcare burden.


Glaucoma is a chronic, degenerative, and irreversible disorder of the optic nerve that causes visual field damage. It affects an estimated 80 million people worldwide, making it the second leading cause of blindness globally. Periodic testing enables early diagnosis and helps prevent visual disability.